

CLAIMS

1. Sustained-release pharmaceutical formulation containing mizolastine, ~~characterized in that it contains~~ *comprising* a core formed of a sustained-release tablet containing mizolastine combined with a fatty matrix and with an organic acid, the said tablet being coated. *B*
2. Sustained-release pharmaceutical formulation according to Claim 1, ~~characterized in that~~ *wherein* the weight ratio between the mizolastine and the organic acid is between 0.3 and 1.
3. Sustained-release pharmaceutical formulation according to either of Claims 1 and 2, characterized in that the fatty matrix is made with hydrogenated castor oil or with hydrogenated lecithins or long-chain fatty acids or triglycerides esterified with medium-chain fatty acids.
4. Sustained-release pharmaceutical formulation according to any one of Claims 1 to 3, characterized in that the organic acid is chosen from maleic, tartaric, malic, fumaric, lactic, citric, adipic and succinic acids in the form of racemates or isomers.
5. Sustained-release pharmaceutical formulation according to ~~any one of Claims 1 to 4~~ *claim 1*, ~~characterized in that~~ *wherein* the organic acid is L-tartaric acid. *B*

6. Sustained-release pharmaceutical, ^{wherein} formulation according to Claim 5, ~~characterized in that~~ the ratio between the mizolastine and the L-tartaric acid is 0.5.

- 5 ~~Claim 1. Formulation according to any one of~~
~~Claims 1 to 6, characterized in that it contains from 1~~
to 25 mg of mizolastine.

AMZ
add B' 7